Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 3077-3081

  Izumi, Kouji ^a   Mizokami, Atsushi ^a   Shima, Takashi ^a   Narimoto, Kazutaka ^a   Sugimoto, Kazuhiro ^b   Kobori, Yoshitomo ^c   Maeda, Yuji ^a   Konaka, Hiroyuki ^a   Koh, Eitetsu ^a   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Bone metastasis; Castration resistant prostate cancer; Overall survival; Tranilast

Indexed keywords

ANTIANDROGEN; DOCETAXEL; INCADRONIC ACID; PROSTATE SPECIFIC ANTIGEN; TRANILAST; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CASTRATION; CLINICAL ARTICLE; DRUG WITHDRAWAL; FOLLOW UP; HEADACHE; HUMAN; JAPANESE; MALE; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SALVAGE THERAPY; SIDE EFFECT; TREATMENT DURATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTHRANILIC ACIDS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77955806313     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Petrylak DP: Chemotherapy for advanced hormone-refractory prostate cancer. Urology 54(6A suppl): 30-35, 1999.
3. Oh WK: Chemotherapy for patients with advanced prostate carcinoma. A new option for therapy. Cancer 88(12 suppl): 3015-3021, 2000.
4. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T and Ito H: Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171(2 Pt 1): 679-683, 2004. (Pubitemid 38090455)
5. Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, Yoshikawa T, Endoh M, Yamanaka Y, Yamamoto T, Satoh Y, Ishida H, Okada K and Takimoto Y: Prospective study of estramustine phosphate for hormone-refractory prostate cancer patients following androgen deprivation therapy. Urol Int 75: 43-49, 2005.
6. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T Fukui T, Ono Y, Inoue H, Shin M, Tsujimoto Y, Takayama H, Aozasa K and Okuyama A: Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93: 1739-1746, 2001.
7. Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET and Namiki M: Tranilast inhibits hormone-refractory prostate cancer cell proliferation and suppresses transforming growth factor-β1-associated osteoblastic changes. Prostate 69: 1222-1234, 2009.
8. Waf1 and p53. J Clin Endocrinol Metab 57: 5610-5617, 2002.
9. 2+-permeable channel. Cell Calcium 22: 75-82, 1997. (Pubitemid 27390421)
10. Yashiro M, Chung YS and Sowa M: Tranilast (N-(3,4-Dimethoxycinnamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer. Anticancer Res 17: 895-900, 1997. (Pubitemid 27182875)
11. Noguchi N, Kawashiri S, Tanaka A, Kato K and Nakaya H: Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma. Oral Oncol 39: 240-247, 2003. (Pubitemid 36255690)
12. Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J and Weller M: N-[3,4-Dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer 93: 53-61, 2001.
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
14. Yagoda A and Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71: 1098-1109, 1993. (Pubitemid 23049638)
15. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
16. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004.
17. Sato S, Takahashi S, Asamoto M, Naiki T, Naiki-Ito A, Asai K and Shirai T: Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro. Prostate 70: 229-238, 2010.
18. Yonou H, Ochiai A, Ashimine S, Maeda H, Horiguchi Y, Yoshioka K, Ogawa Y, Hatano T and Tachibana M: The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer. Prostate 67: 999-1009, 2007. (Pubitemid 46828933)
19. waf1. Atherosclerosis 143: 307-313, 1999. (Pubitemid 29166911)
20. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S and Pienta KJ: Rapid ('warm') autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6: 1038-1045, 2000. (Pubitemid 30159365)
21. Matsumoto A, Inoue A, Yokoi S, Nozumi K, Miyazaki K, Hosoki S, Nagata M and Yamaguchi K: Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Int J Urol 16: 687-691, 2009.
22. Murahashi K, Yashiro M, Inoue T, Nishimura S, Matsuoka T, Sawada T, Sowa M and Hirakawa-Ys Chung K: Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer. Int J Oncol 13: 1235-1240, 1998. (Pubitemid 28551550)
23. Yatsunami J, Aoki S, Fukuno Y, Kikuchi Y, Kawashima M and Hayashi SI: Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells. Int J Oncol 17: 1151-1156, 2000.
24. Fan J, Stanfield J, Guo Y, Karam JA, Frenkel E, Sun X and Hsieh JT: Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer. Clin Cancer Res 15: 1200-1207, 2008. (Pubitemid 351302569)
25. Chang SS and Kibel AS: The role of systemic cytotoxic therapy for prostate cancer. BJU Int 103: 8-17, 2009.